Elekta flagged by Deutsche Bank, shares stay below revised target
22.06.2026 - 19:02:05 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-22, 18:59.
Elekta (SE0000163628) remains on the radar after a fresh analyst move. Deutsche Bank has cut its price target to 52 Swedish kronor from 60 and reiterated a Hold rating, while the shares trade on Nasdaq Stockholm under the ticker EKTA B.
Deutsche Bank trims expectations
According to a 2026-06-22 note summarized by MarketScreener, Deutsche Bank now sets its Elekta price target at 52 kronor, down from 60 kronor, and keeps its recommendation at Hold, citing a more cautious stance on the earnings trajectory. The Deutsche Bank update on Elekta highlights that the new target still sits modestly above the latest closing price.
The same source lists the most recent Elekta close around 48.69 kronor, implying that the shares trade roughly 6 percent below the revised target, while the stock has declined more than 14 percent over the past 12 months in Stockholm trading. MarketScreener price and performance data for EKTA B show the company lagging some broader healthcare benchmarks over that period.
How Elekta compares with peers
In the radiotherapy and oncology equipment space, Elekta competes with US-listed players such as Varian Medical Systems, now part of Siemens Healthineers and represented indirectly in indices like the DAX via its parent, and with niche specialists like Accuray on Nasdaq. Business profiles on Elekta describe a focus on linear accelerators, stereotactic radiosurgery and software for cancer care.
While Deutsche Bank stays neutral, some market observers note that Elekta operates in a structurally growing market for oncology treatments, but faces pricing and investment cycle sensitivities that can weigh on margins versus larger diversified peers such as Siemens Healthineers and GE HealthCare. MarketBeat data on Elekta’s US ADR EKTAY show a modest market capitalization and limited liquidity compared with these giants.
All news and analysis on the Elekta shares
Track recent ratings, price data and background reports on Elekta, from analyst target changes to sector comparisons in radiotherapy equipment.
What the company sells in oncology
Elekta’s core business is radiotherapy and radiosurgery systems, with its Elekta Unity MR-Linac and Versa HD linear accelerators among the flagship platforms used in hospitals worldwide for precision cancer treatment. The group also develops oncology information systems and treatment planning software to integrate imaging, planning and delivery.
Where the stock trades today
The Elekta shares (SE0000163628) last traded on Nasdaq Stockholm at 48.69 Swedish kronor on 2026-06-22, according to recent exchange and MarketScreener data.
Key data on the Elekta shares
- Company: Elekta AB (publ)
- ISIN: SE0000163628
- WKN: 895154
- Ticker: EKTA B
- Trading venue: Nasdaq Stockholm
- Price (as of 2026-06-22, 18:30): 48.69 SEK
- Market cap: approximately 19 billion SEK (as of 2026-06-22)
- Sector / industry: Health Care Equipment & Supplies, radiation oncology
- Index membership: Included in the OMX Stockholm benchmarks and healthcare sector indices
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.
